use | (1R,2R)-2-(3, 4-difluorophenyl) cyclopropanecarboxylate ethyl ester is a key intermediate in the synthesis of ticagrelor (ticagrelor). Ticagrel, chemical name [1S-[1 α,2 α,3 β(1S,2R),5 β]]-3-[7-[2-(3, 4-difluorophenyl)-cyclopropylamine]-5-(propylthio)-3H-1,2, 3-triazolo [4,5-d] pyrimidine-3-yl]-5-(2-hydroxyethoxy) cyclopentan-1, 2-diol is an oral antiplatelet drug developed by AstraZeneca (AstraZenecaAB). The drug can reversibly act on ADPP2Y12 receptors, has a significant inhibitory effect on platelet aggregation caused by ADP, and has a rapid oral effect. It is clinically used to reduce the incidence of thrombotic cardiovascular events in patients with acute coronary syndrome. |